+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global RNAi Therapeutics Market: Analysis By Molecule Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2026

  • ID: 5566554
  • Report
  • March 2022
  • Region: Global
  • 109 Pages
  • Daedal Research
The report provides an in-depth analysis of the Global RNAi therapeutics market by value, by molecule type, by application, by region, etc. The report provides a regional analysis of the RNAi therapeutics market, including North America (The US, Canada, and Mexico), Europe, Asia Pacific, Middle East & Africa, and Latin America. The report further provides a detailed analysis of the US market on the basis of molecule type, and application. The report also provides an analysis of the COVID-19 impact on the RNAi therapeutics market.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall RNAi therapeutics market has also been forecasted for the period 2022-2026, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global RNAi therapeutics market is concentrated. The key players of the global RNAi therapeutics market are Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., and Silence Therapeutics Inc. are also profiled with their financial information and respective business strategies.


Company Coverage


  • Moderna Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • Silence Therapeutics Inc.



Regional Coverage


  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Table of Contents

1. Executive Summary
2. Introduction
2.1 RNA-based Therapeutics:  An Overview
2.1.1 Types of RNA-based Therapeutics
2.1.2 History of RNA-based Therapeutics
2.1.3 Advantages of RNA-based Therapeutics
2.2 RNA interference (RNAi) Therapeutics:  An Overview
2.2.1 Mechanism of RNA interference (RNAi) Therapeutics
2.2.2 Steps of RNA interference (RNAi) Therapeutics
2.2.3 Applications of RNA interference (RNAi) Therapeutics
2.2.4 RNAi Therapeutics:  Platform Comparison
2.2.5 Advantages and Disadvantages of RNA interference (RNAi) Therapeutics
2.3 RNA interference (RNAi) Therapeutics:  Segmentation by Molecule Type
2.4 RNA interference (RNAi) Therapeutics:  Segmentation by Application
3. Global Market Analysis
3.1 Global RNAi Therapeutics Market:  An Analysis
3.1.1 Global RNAi Therapeutics Market by Value
3.1.2 Global RNAi Therapeutics Market by Molecule Type (Small Interfering RNAs (siRNA) and Micro RNAs (miRNA))
3.1.3 Global RNAi Therapeutics Market by Application (Oncology, Cardiovascular Disorders, Respiratory Disorders, Renal Diseases, Genetic Disorders, Neurodegenerative Disorders, Infectious Diseases, and Other)
3.1.4 Global RNAi Therapeutics Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
3.2 Global RNAi Therapeutics Market:  Molecule Type Analysis
3.2.1 Global Small Interfering RNAs (siRNA) Therapeutics Market by Value
3.2.2 Global Micro RNAs (miRNA) Therapeutics Market by Value
3.3 Global RNAi Therapeutics Market:  Application Analysis
3.3.1 Global Oncology RNAi Therapeutics Market by Value
3.3.2 Global Cardiovascular Disorders RNAi Therapeutics Market by Value
3.3.3 Global Respiratory Disorders RNAi Therapeutics Market by Value
3.3.4 Global Renal Diseases RNAi Therapeutics Market by Value
3.3.5 Global Genetic Disorders RNAi Therapeutics Market by Value
3.3.6 Global Neurodegenerative Disorders RNAi Therapeutics Market by Value
3.3.7 Global Infectious Diseases RNAi Therapeutics Market by Value
3.3.8 Global Other RNAi Therapeutics Market by Value
4. Regional Market Analysis
4.1 North America RNAi Therapeutics Market:  An Analysis
4.1.1 North America RNAi Therapeutics Market by Value
4.1.2 North America RNAi Therapeutics Market by Molecule Type (Small Interfering RNAs (siRNA) and Micro RNAs (miRNA))
4.1.3 North America Small Interfering RNAs (siRNA) Therapeutics Market by Value
4.1.4 North America Micro RNAs (miRNA) Therapeutics Market by Value
4.1.5 North America RNAi Therapeutics Market by Application (Oncology, Cardiovascular Disorders, Respiratory Disorders, Renal Diseases, Genetic Disorders, Neurodegenerative Disorders, Infectious Diseases, and Other)
4.1.6 North America Oncology RNAi Therapeutics Market by Value
4.1.7 North America Cardiovascular Disorders RNAi Therapeutics Market by Value
4.1.8 North America Respiratory Disorders RNAi Therapeutics Market by Value
4.1.9 North America Renal Diseases RNAi Therapeutics Market by Value
4.1.10 North America Genetic Disorders RNAi Therapeutics Market by Value
4.1.11 North America Neurodegenerative Disorders RNAi Therapeutics Market by Value
4.1.12 North America Infectious Diseases RNAi Therapeutics Market by Value
4.1.13 North America Other RNAi Therapeutics Market by Value
4.1.14 North America RNAi Therapeutics Market by Region (The US, Canada, and Mexico)
4.1.15 The US RNAi Therapeutics Market by Value
4.1.16 The US RNAi Therapeutics Molecule Type Market by Value
4.1.17 The US RNAi Therapeutics Application Market by Value
4.1.18 Canada RNAi Therapeutics Market by Value
4.1.19 Mexico RNAi Therapeutics Market by Value
4.2 Europe RNAi Therapeutics Market:  An Analysis
4.2.1 Europe RNAi Therapeutics Market by Value
4.3 Asia Pacific RNAi Therapeutics Market:  An Analysis
4.3.1 Asia Pacific RNAi Therapeutics Market by Value
4.4 Middle East & Africa RNAi Therapeutics Market:  An Analysis
4.4.1 Middle East & Africa RNAi Therapeutics Market by Value
4.5 Latin America RNAi Therapeutics Market:  An Analysis
4.5.1 Latin America RNAi Therapeutics Market by Value
5. Impact of COVID
5.1 Impact of COVID-19 on Global RNAi Therapeutics Market
6. Market Dynamics
6.1 Growth Driver
6.1.1 Increasing Investments in RNAi Therapies
6.1.2 Rise in Incidence of Cancer
6.1.3 Rising Prevalence of Diabetes
6.1.4 Increased Prevalence of Infectious Diseases
6.1.5 Rising Genetic and Metabolic Disorders
6.2 Challenges
6.2.1 High Development Cost of RNA Interference-based Drugs
6.2.2 Stringent Regulations and Long Product Approval Process
6.2.3 Unstable Potentially Immunogenic Nature of RNA
6.3 Market Trends
6.3.1 Rapid Clinical-developments in RNAi Therapeutics for Cancer Application
6.3.2 RNA Interference Therapeutics for Cardiac Regeneration
6.3.3 Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics
6.3.4 Folate Receptor-Mediated siRNA Delivery
6.3.5 Growing Focus on Personalized Medicines
6.3.6 New AI Technologies in RNAi Therapeutics Market
7. Competitive Landscape
7.1 Global RNAi Therapeutics Market Players:  A Financial Comparison
7.2 Global RNAi Therapeutics Market Players:  Technology Comparison
7.3 Global RNAi Therapeutics Market Players:  Product & Services Comparison
7.4 Global RNAi Therapeutics Market Players:  Research & Development Expenses Comparison
8. Company Profiles
8.1 Moderna Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Alnylam Pharmaceuticals Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Ionis Pharmaceuticals Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Silence Therapeutics Inc.
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
List of Figures and Tables
Figure 1: Types of RNA-based Therapeutics
Figure 2: History of RNA-based Therapeutics
Figure 3: Advantages of RNA-based Therapeutics
Figure 4: Mechanism of RNA interference (RNAi) Therapeutics
Figure 5: Steps of RNA interference (RNAi) Therapeutics
Figure 6: Applications of RNA interference (RNAi) Therapeutics
Figure 7: Advantages and Disadvantages of RNA interference (RNAi) Therapeutics
Figure 8: RNA interference (RNAi) Therapeutics Segmentation by Molecular Type
Figure 9: RNA interference (RNAi) Therapeutics Segmentation by Application
Figure 10: Global RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 11: Global RNAi Therapeutics Market by Value; 2022-2026 (US$ Billion)
Figure 12: Global RNAi Therapeutics Market by Molecule Type; 2021 (Percentage, %)
Figure 13: Global RNAi Therapeutics Market by Application; 2021 (Percentage, %)
Figure 14: Global RNAi Therapeutics Market by Region; 2021 (Percentage, %)
Figure 15: Global Small Interfering RNAs (siRNA) Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 16: Global Small Interfering RNAs (siRNA) Therapeutics Market by Value; 2022-2026 (US$ Billion)
Figure 17: Global Micro RNAs (miRNA) Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 18: Global Micro RNAs (miRNA) Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 19: Global Oncology RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 20: Global Oncology RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 21: Global Cardiovascular Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 22: Global Cardiovascular Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 23: Global Respiratory Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 24: Global Respiratory Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 25: Global Renal Diseases RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 26: Global Renal Diseases RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 27: Global Genetic Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 28: Global Genetic Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 29: Global Neurodegenerative Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 30: Global Neurodegenerative Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 31: Global Infectious Diseases RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 32: Global Infectious Diseases RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 33: Global Other RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 34: Global Other RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 35: North America RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 36: North America RNAi Therapeutics Market by Value; 2022-2026 (US$ Billion)
Figure 37: North America RNAi Therapeutics Market by Molecule Type; 2021 (Percentage, %)
Figure 38: North America Small Interfering RNAs (siRNA) Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 39: North America Small Interfering RNAs (siRNA) Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 40: North America Micro RNAs (miRNA) Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 41: North America Micro RNAs (miRNA) Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 42: North America RNAi Therapeutics Market by Application; 2021 (Percentage, %)
Figure 43: North America Oncology RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 44: North America Oncology RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 45: North America Cardiovascular Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 46: North America Cardiovascular Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 47: North America Respiratory Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 48: North America Respiratory Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 49: North America Renal Diseases RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 50: North America Renal Diseases RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 51: North America Genetic Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 52: North America Genetic Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 53: North America Neurodegenerative Disorders RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 54: North America Neurodegenerative Disorders RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 55: North America Infectious Diseases RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 56: North America Infectious Diseases RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 57: North America Other RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 58: North America Other RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 59: North America RNAi Therapeutics Market by Region; 2021 (Percentage, %)
Figure 60: The US RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 61: The US RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 62: The US RNAi Therapeutics Molecule Type Market by Value; 2021-2026 (US$ Million)
Figure 63: The US RNAi Therapeutics Application Market by Value; 2021-2026 (US$ Million)
Figure 64: Canada RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 65: Canada RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 66: Mexico RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 67: Mexico RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 68: Europe RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 69: Europe RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 70: Asia Pacific RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 71: Asia Pacific RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 72: Middle East & Africa RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 73: Middle East & Africa RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 74: Latin America RNAi Therapeutics Market by Value; 2020-2021 (US$ Million)
Figure 75: Latin America RNAi Therapeutics Market by Value; 2022-2026 (US$ Million)
Figure 76: Global New Cancer Cases Diagnosed; 2018 & 2020 (Million)
Figure 77: Global Diabetes Prevalence among Adults (20–79 years); 2021 & 2045 (Percentage, %)
Figure 78: Global RNAi Therapeutics Market Players: Research & Development Expenses Comparison; 2017-2020 (US$ Million)
Figure 79: Moderna Inc. Total Revenues; 2017-2021 (US$ Million)
Figure 80: Alnylam Pharmaceuticals Inc. Revenue; 2017-2021 (US$ Million)
Figure 81: Alnylam Pharmaceuticals Inc. Net Product Revenue by Product; 2021 (Percentage, %)
Figure 82: Alnylam Pharmaceuticals Inc. Net Product Revenue by Region; 2021 (Percentage, %)
Figure 83: Ionis Pharmaceuticals Inc. Revenue; 2017-2021 (US$ Million)
Figure 84: Silence Therapeutics Inc. Total Revenue; 2016-2020 (US$ Million)
Figure 85: Silence Therapeutics Inc. Total Revenue by Region; 2020 (Percentage, %)
Table 1: RNAi Therapeutics: Platform Comparison
Table 2: Increasing Investment Deals in RNAi Therapeutics; 2018-2021
Table 3: Current Clinical Status of RNAi Therapeutics for Cancer Treatment
Table 4: Global RNAi Therapeutics Market Players: A Financial Comparison; 2020/2021
Table 5: Global RNAi Therapeutics Market Players: Technology Comparison
Table 6: Global RNAi Therapeutics Market Players: Product & Services Comparison

Executive Summary

The RNAi therapeutics market can be segmented on the basis of molecule type (small interference RNA (siRNA), and micro RNA (miRNA)), and application (oncology, cardiovascular disorders, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others).

While most of the industries worldwide suffered a negative impact of COVID-19, the RNAi therapeutics market witnessed a positive impact on it. Initially, the market witnessed a sudden spike in the demand, since the relevance of RNAi research in understanding the COVID-19 virus started growing mainly during the initial worldwide outbreak of COVID-19, in 2020. Later in the year 2020, the market witnessed several investments from both public and private investors in pharma R&D laboratories to conduct various studies and experiments to find out vaccines to prevent the spread of virus. Many pharmaceutical businesses are actively commercializing their medications in order to improve profits and attract additional investment capital.

The global RNAi therapeutics market has increased during the years 2020-2021 and projections are made that the market would rise in the next four years i.e. 2022-2026. The global RNAi therapeutics market is expected to increase due to significant increase in investment, increased prevalence of infectious diseases, rise in incidence of cancer, rising prevalence of diabetes, and rising genetic and metabolic disorders. Yet the market faces some challenges such as, high development cost of RNA interference-based drugs, stringent regulations and long product approval process, unstable potentially immunogenic nature of RNA, etc.

Companies Mentioned

  • Moderna Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • Silence Therapeutics Inc.